Market Place
Sourcing Support
All News #Library
Biotech
ORIC Pharma Highlights Rinzimetostat`s Prostate Cancer Potential
19 Apr 2026 //
FIRSTWORD PHARMA
ORIC Pharmaceuticals Picks Rinzimetostat RP3D for Phase 3
31 Mar 2026 //
GLOBENEWSWIRE
ORIC To Report Rinzimetostat Ph1b Combo Data In mCRPC
27 Mar 2026 //
GLOBENEWSWIRE
ORIC Pharma Unveils (ORIC-944) Preclinical Data At AACR 2026
17 Mar 2026 //
GLOBENEWSWIRE
ORIC Pharma Reveals 2025 Financials And Operations
23 Feb 2026 //
GLOBENEWSWIRE
ORIC Pharma Showcases Enozertinib`s Strong Efficacy In NSCLC
05 Dec 2025 //
GLOBENEWSWIRE
ORIC-114 Late-Breaking Oral for EGFR Exon 20 NSCLC at ESMO 2025
03 Dec 2025 //
GLOBENEWSWIRE
ORIC Pharma Unveils ORIC-114 Poster for HER2 Exon 20 NSCLC
01 Dec 2025 //
GLOBENEWSWIRE
ORIC Pharma Joins 8Th Evercore Healthcare Conference
24 Nov 2025 //
GLOBENEWSWIRE
ORIC Pharma`s ORIC-944 Trial Shows Best-in-Class Results
13 Nov 2025 //
GLOBENEWSWIRE
ORIC Pharma Reveals Cancer Research Publication On Enozertinib
06 Nov 2025 //
GLOBENEWSWIRE
ORIC Presents Data on ORIC-944 Showing Promise in Solid Tumors
27 Oct 2025 //
GLOBENEWSWIRE
ORIC Pharma Presents Preclinical Data on ORIC-944 at AACR 2025
28 Apr 2025 //
GLOBENEWSWIRE
ORIC Signs Supply Deal To Study ORIC-114 With Amivantamab In NSCLC
13 Jan 2025 //
GLOBENEWSWIRE
ORIC Pharmaceuticals Reports Q2 2024 Results And Operational Updates
12 Aug 2024 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.